Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for neuropsychiatric and neurological disorders, specifically focusing on central nervous system (CNS) conditions. The company's mission is to address significant unmet medical needs by leveraging its proprietary drug development platform to create innovative treatments that can offer meaningful improvements in the lives of patients. Headquartered in South San Francisco, California, Vistagen aims to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders.

Vistagen's core strategy revolves around its unique "pherine" platform, which utilizes intranasal administration to target nose-to-brain neurocircuitry for rapid and non-systemic therapeutic effects. This approach aims to provide therapeutic benefits without requiring systemic absorption or direct binding to brain neurons, potentially offering a differentiated safety and efficacy profile. The company's pipeline includes several clinical-stage product candidates: fasedienol (PH94B) for social anxiety disorder, itruvone (PH10) for major depressive disorder, refisolone (PH80) for menopausal vasomotor symptoms and premenstrual dysphoric disorder, PH15 for psychomotor and cognitive impairment due to mental fatigue, and AV-101 (prosadil) for major depressive disorder, suicidal ideation, and neuropathic pain.

Shawn K. Singh serves as the President and Chief Executive Officer of Vistagen. In December 2025, the company announced that its PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint, leading to the implementation of cash preservation measures and a 20% staff reduction to extend its financial runway into 2027. Despite this setback, Vistagen received a "Study May Proceed" letter from the FDA in April 2026 for further Phase 2 clinical development of refisolone for vasomotor symptoms due to menopause. The company is also currently facing several securities class action lawsuits.